MDMA was once known mainly as a party drug. Over decades, researchers asked a different question: could its effects, which include reduced fear and increased trust, help people process trauma in psychotherapy? The largest trials say “possibly,” and the details matter.

The problem being addressed

PTSD can follow combat, assault, accidents, abuse, and other severe events. Symptoms include intrusive memories, nightmares, hypervigilance, and emotional numbing. First-line treatments exist, including trauma-focused psychotherapy and the SSRIs sertraline and paroxetine, but many people do not respond fully or drop out. The hope for MDMA was that it could make hard therapy tolerable. It was never meant as a stand-alone drug. It was tested as an adjunct to structured psychotherapy.

How the trials worked

The program was led by the Multidisciplinary Association for Psychedelic Studies (MAPS) and its public benefit subsidiary, which became Lykos Therapeutics in 2024. Two Phase 3 trials, MAPP1 and MAPP2, tested the approach in adults with moderate to severe PTSD. Participants received three sessions of MDMA or placebo, each lasting several hours, with two trained therapists present, plus preparation and integration sessions without the drug. Screening excluded many medical and psychiatric conditions, and sessions took place in a controlled clinical setting.

The results

In MAPP1 (published in Nature Medicine in 2021), about 67% of the MDMA group no longer met PTSD criteria afterward, compared with about 32% in the placebo-plus-therapy group. MAPP2 (2023) found about 71% against about 48%. Depression symptoms and functional impairment also improved more with MDMA. Both groups improved, which shows how much good therapy alone can do.

Why the FDA said no

In June 2024, an FDA advisory committee voted 9 to 2 that the data did not show MDMA-assisted therapy was effective for PTSD. In August 2024 the agency issued a complete response letter declining approval and asked for another Phase 3 trial. The concerns included:

• Functional unblinding. MDMA’s effects are obvious. Most participants and therapists could tell who got the drug, which can inflate subjective ratings.
• Safety data gaps, including cardiovascular risks and how to monitor for potential abuse.
• Trial conduct concerns, including reports of misconduct involving some staff. Several earlier papers were retracted by a journal over protocol violations.
• Expectancy effects, which are hard to separate from drug effects in a therapy trial.

What has happened since

Lykos lost roughly 75% of its staff after the rejection. In January 2025 the company described a “productive” meeting with the FDA and said it was charting a path toward an independent third-party review of earlier Phase 3 data and an additional Phase 3 trial. As of this writing I could not confirm a new approval date, so readers should check current news. Other researchers, including academic groups studying MDMA combined with exposure therapy, are also working on the question.

Safety findings

Common effects during and after sessions included nausea, jaw tightness, reduced appetite, anxiety, and fatigue. MDMA raises heart rate and blood pressure, which is a major reason for cardiovascular screening. Supervised trial results cannot be assumed to apply to street MDMA, which varies in purity and is often adulterated.

What the numbers do and don’t tell you

• The effect looks large, but part of it likely reflects expectation and the quality of the therapy.
• The placebo group’s improvement, close to half in MAPP2, is itself striking.
• The study population was screened and carefully selected.
• Long-term durability data is thinner than for standard treatments.

What readers should take away

Evidence-based PTSD treatment exists today. Trauma-focused therapies such as prolonged exposure, cognitive processing therapy, and EMDR have strong track records, and a clinician can help match a person to the right option. MDMA-assisted therapy remains investigational. Using street MDMA to self-treat trauma is not what was tested: the trials delivered pharmaceutical-grade product, screening, trained therapists, and aftercare. People who use drugs outside clinical settings can reduce harm through drug checking and by not using alone, and organizations such as DanceSafe (dancesafe.org) and TripSit (tripsit.me) publish guidance.

The takeaway

MDMA-assisted therapy showed meaningful improvement in two Phase 3 trials, and regulators concluded the evidence was not yet strong enough. That is a reminder that promising and proven are different things.

Sources: NPR/Michigan Public coverage of the FDA decision (Aug 2024); Lucid News on the advisory committee vote; Fierce Biotech on Lykos’ post-rejection plan; MAPP1 and MAPP2 publications.